Kunan Bangphumi1,2, Chuleeporn Kittiviriyakul1,2, Pasarapa Towiwat1,3, Pornchai Rojsitthisak4,3, Phisit Khemawoot5,6. 1. Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. 2. Graduate School of Chulalongkorn University, Chulalongkorn University, Bangkok, Thailand. 3. Chulalongkorn University Drugs and Health Product Innovation Promotion Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. 4. Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. 5. Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Phisit.K@chula.ac.th. 6. Chulalongkorn University Drugs and Health Product Innovation Promotion Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Phisit.K@chula.ac.th.
Abstract
BACKGROUND AND OBJECTIVES: Curcumin is the major bioactive component of turmeric, but has poor oral bioavailability that limits its clinical applications. To improve the in vitro solubility and alkaline stability, we developed a prodrug of curcumin by succinylation to obtain curcumin diethyl disuccinate, with the goal of improving the oral bioavailability of curcumin. METHODS: The in vivo pharmacokinetic profile of curcumin diethyl disuccinate was compared with that of curcumin in male Wistar rats. Doses of curcumin 20 mg/kg intravenous or 40 mg/kg oral were used as standard regimens for comparison with the prodrug at equivalent doses in healthy adult rats. Blood, tissues, urine, and faeces were collected from time zero to 48 h after dosing to determine the prodrug level, curcumin level and a major metabolite by liquid chromatography-tandem spectrometry. RESULTS: The absolute oral bioavailability of curcumin diethyl disuccinate was not significantly improved compared with curcumin, with both compounds having oral bioavailability of curcumin less than 1 %. The major metabolic pathway of the prodrug was rapid hydrolysis to obtain curcumin, followed by glucuronidation. Interestingly, curcumin diethyl disuccinate gave superior tissue distribution with higher tissue to plasma ratio of curcumin and curcumin glucuronide in several organs after intravenous dosing at 1 and 4 h. The primary elimination route of curcumin glucuronide occurred via biliary and faecal excretion, with evidence of an entry into the enterohepatic circulation. CONCLUSION: Curcumin diethyl disuccinate did not significantly improve the oral bioavailability of curcumin due to first pass metabolism in the gastrointestinal tract. Further studies on reduction of first pass metabolism are required to optimise delivery of curcumin using a prodrug approach.
BACKGROUND AND OBJECTIVES:Curcumin is the major bioactive component of turmeric, but has poor oral bioavailability that limits its clinical applications. To improve the in vitro solubility and alkaline stability, we developed a prodrug of curcumin by succinylation to obtain curcumin diethyl disuccinate, with the goal of improving the oral bioavailability of curcumin. METHODS: The in vivo pharmacokinetic profile of curcumin diethyl disuccinate was compared with that of curcumin in male Wistar rats. Doses of curcumin 20 mg/kg intravenous or 40 mg/kg oral were used as standard regimens for comparison with the prodrug at equivalent doses in healthy adult rats. Blood, tissues, urine, and faeces were collected from time zero to 48 h after dosing to determine the prodrug level, curcumin level and a major metabolite by liquid chromatography-tandem spectrometry. RESULTS: The absolute oral bioavailability of curcumin diethyl disuccinate was not significantly improved compared with curcumin, with both compounds having oral bioavailability of curcumin less than 1 %. The major metabolic pathway of the prodrug was rapid hydrolysis to obtain curcumin, followed by glucuronidation. Interestingly, curcumin diethyl disuccinate gave superior tissue distribution with higher tissue to plasma ratio of curcumin and curcumin glucuronide in several organs after intravenous dosing at 1 and 4 h. The primary elimination route of curcumin glucuronide occurred via biliary and faecal excretion, with evidence of an entry into the enterohepatic circulation. CONCLUSION:Curcumin diethyl disuccinate did not significantly improve the oral bioavailability of curcumin due to first pass metabolism in the gastrointestinal tract. Further studies on reduction of first pass metabolism are required to optimise delivery of curcumin using a prodrug approach.
Authors: Liu Zhongfa; Ming Chiu; Jiang Wang; Wei Chen; Winston Yen; Patty Fan-Havard; Lisa D Yee; Kenneth K Chan Journal: Cancer Chemother Pharmacol Date: 2011-10-04 Impact factor: 3.333
Authors: Aynun N Begum; Mychica R Jones; Giselle P Lim; Takashi Morihara; Peter Kim; Dennis D Heath; Cheryl L Rock; Mila A Pruitt; Fusheng Yang; Beverly Hudspeth; Shuxin Hu; Kym F Faull; Bruce Teter; Greg M Cole; Sally A Frautschy Journal: J Pharmacol Exp Ther Date: 2008-04-16 Impact factor: 4.030
Authors: Ana Brotons-Canto; Carlos J González-Navarro; Ana Gloria Gil; Eduardo Asin-Prieto; María José Saiz; Josep Manuel Llabrés Journal: Pharmaceutics Date: 2021-03-09 Impact factor: 6.321